drug
ranibizumab SR
Marketedupdated 5mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval18 co-mentions · 9 sources
- drugBYOOVIZ16 co-mentions · 8 sources
- drugranibizumab14 co-mentions · 14 sources
- drugranibizumab biosimilar13 co-mentions · 13 sources
- companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
- companyXbrane Biopharma AB5 co-mentions · 5 sources
- tagOphthalmology5 co-mentions · 5 sources
- tagBiosimilar5 co-mentions · 5 sources
all catalysts(0)
nothing on the calendar yet
Trials studying ranibizumab SR
- phase3A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- —A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- phase4A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
- phase3A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
- phase3Extension Study for the Port Delivery System With Ranibizumab (Portal)
- phase2Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
- phase2Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
- phase3A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
News(1)
- Merck sees pivotal victory for $3B eye disease prospectMerck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…fiercebiotech · 6d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that